Refractory Inflammatory Arthritis revised definition and model

1	SHORT TITLE: Refractory Inflammatory Arthritis revised definition and model			
2	MANUSCRIPT TITLE: Refractory Inflammatory Arthritis definition and mode			
3	generated through patient and multi-disciplinary professional modified Delphi process			
4	Authors: Hema Chaplin ¹ MSc, Ailsa Bosworth ² MBE, Carol Simpson ³ , Kate Wilkins ³ ,			
5	Jessica Meehan ¹ MSc, Elena Nikiphorou ³ MBBS, MRCP, MD(Res), Rona Moss-			
6	Morris ¹ PhD, *Heidi Lempp ³ PhD, *Sam Norton ^{1,3} PhD. *Joint Last Author			
7	Affiliations: ¹ Health Psychology Section, Institute of Psychiatry, Psychology and			
8	Neuroscience, King's College London, London, UK. ² National Rheumatoid Arthritis			
9	Society; ³ Centre for Rheumatic Diseases, King's College London, London, UK.			
10	Corresponding Author: Hema Chaplin, <u>hema.chaplin@kcl.ac.uk</u> , (+44)20 7188			
11	0192, Health Psychology Section, Institute of Psychiatry, Psychology &			
12	Neuroscience, King's College London, 5th Floor Bermondsey Wing, Guy's Hospital,			
13	London Bridge, London SE1 9RT.ORCID ID: 0000-0002-9402-9669			
14	CRediT Author Statement: Hema Chaplin: Conceptualization, Methodology, Formal			
15	analysis, Investigation, Writing – Original Draft, Visualization, Project Administration,			
16	Funding Acquisition. Ailsa Bosworth: Writing - Review & Editing, Project			
17	Administration (Nominal Group), Supervision (Patient Representative). Carol			
18	Simpson: Writing - Review & Editing, Supervision (Patient Representative). Kate			
19	Wilkins: Writing - Review & Editing, Supervision (Patient Representative). Jessica			
20	Meehan: Formal analysis, Writing - Review & Editing. Elena Nikiphorou: Writing -			
21	Review & Editing, Supervision (Clinical). Rona Moss-Morris: Methodology, Writing -			
22	Review & Editing, Visualization, Supervision (Academic). Heidi Lempp:			
23	Conceptualization, Methodology, Formal analysis, Writing – Original Draft, Writing -			
24	Review & Editing, Visualization, Supervision (Academic), Funding Acquisition. Sam NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.			

Refractory Inflammatory Arthritis revised definition and model

25	Norton: Conceptualization, Methodology, Formal analysis, Writing – Original Draft,		
26	Writing - Review & Editing, Visualization, Supervision (Academic), Fundin		
27	Acquisition.		
28	Ethical Approval: Full NHS ethical approval granted in July 2018 by London -		
29	Hampstead Research Ethics Committee (18/LO/1171).		
30	Conflict of Interests: None		
31	Word Count: 5,593 plus 294/300 Abstract		
32	References: 125		
33	Funding: This paper represents independent research funded by the National Institute		
34	for Health Research (NIHR) Maudsley Biomedical Research Centre at South London		
35	and Maudsley NHS Foundation Trust and King's College London, in the form of a PhD		
36	Studentship (IS-BRC-1215-20018) for the first author (HC). The views expressed are		
37	those of the author(s) and not necessarily those of the NHS, the NIHR or the		
38	Department of Health and Social Care.		
39	Data availability: The data generated that support the findings of this study are		
40	available from the corresponding author, HC, upon reasonable request.		
41			
42			
43			
44			
45			

Refractory Inflammatory Arthritis revised definition and model

47

ABSTRACT

Objective: Various definitions have been proposed for Refractory Disease in people with Rheumatoid Arthritis; however, none were generated for Polyarticular Juvenile Idiopathic Arthritis or involving adult and paediatric multidisciplinary healthcare professionals and patients. The study aim is to redefine Refractory Disease, using Delphi methodology.

53 **Methods:** Three rounds of surveys (one nominal group and two online (2019-2020)) 54 to achieve consensus using a predetermined cut-off were conducted voting on: a) 55 name, b) treatment and inflammation, c) symptoms and impact domains, and d) rating 56 of individual components within domains. Theoretical application of the definition was 57 conducted through a scoping exercise.

Results: Votes were collected across three rounds from Patients, Researchers and 58 (n=106). healthcare professional 59 nine multi-disciplinary groups Refractory Inflammatory Arthritis was the most popular name. Regarding treatment and 60 61 inflammation, these were voted to be kept broad rather than specifying numbers/cutoffs. From 10 domains identified to capture symptoms and disease impact, six 62 domains reached consensus for inclusion: 1) Disease Activity, 2) Joint Involvement, 63 3) Pain, 4) Fatigue, 5) Functioning and Quality of Life, and 6) Disease-Modifying Anti-64 Rheumatic Drug Experiences. Within these domains, 18 components, from an initial 65 pool (n=73), were identified as related and important to capture multi-faceted 66 presentation of Refractory Inflammatory Arthritis, specifically in Rheumatoid Arthritis 67 and Polyarticular Juvenile Idiopathic Arthritis. Feasibility of the revised definition was 68 established (2022-2023) with good utility as was applied to 82% of datasets (n=61) 69 incorporating 20 outcome measures, with two further measures added to increase its 70 utility and coverage of Pain and Fatigue. 71

Refractory Inflammatory Arthritis revised definition and model

72	Conclusion: Refractory Inflammatory Arthritis has been found to be broader than not		
73	achieving low disease activity, with wider biopsychosocial components and factors		
74	incorporating Persistent Inflammation or Symptoms identified as important. This		
75	definition needs further refinement to assess utility as a classification tool to identify		
76	patients with unmet needs.		
77	Keywords: Delphi, Multi-disciplinary Healthcare-Professionals, Persistent Symptoms,		
78	Polyarticular JIA, Refractory Disease, Rheumatoid Arthritis.		
79			
80	What is already known on this topic		
00			
81	• In recent years within Rheumatology, parallel bodies of work have reached		
82	similar conclusions regarding the broadening of the Refractory or the wider		
83	Difficult-to-Treat concept.		
84	What this study adds		
85	 In this paper, we provide a different angle to define, measure, and 		
86	conceptualise Refractory Inflammatory Arthritis, using health psychology theory		
87	across Polyarticular Juvenile Idiopathic Arthritis and Rheumatoid Arthritis with		
88	the input of patients, rheumatologists, and multi-disciplinary healthcare		
89	professionals.		
90	• We support and extend recent definitions of refractory rheumatoid arthritis by		
91	detailing a three-part definition identified as important to both patients and multi-		
92	disciplinary healthcare professionals that can also be applied to Polyarticular		
93	Juvenile Idiopathic Arthritis: 1) Treatment, 2) Inflammation, and 3) Symptoms		
94	and Impact with 18 specific components within 6 domains. The Refractory		
95	Inflammatory Arthritis definition can be operationalised as a classification tool		

Refractory Inflammatory Arthritis revised definition and model

- 96 using 22 routinely collected data points to identify those who need further97 targeted support and treatment.
- We have applied a biopsychosocial formulation model for Refractory Inflammatory Arthritis covering perpetuating and protective factors to guide management strategies and present wider contextual factors involved in the experience of Refractory Inflammatory Arthritis.

102 How this study might affect research, practice or policy

- The development of the Refractory Inflammatory Arthritis definition presented
 here included consideration of content and discriminant validity indicators to
 provide a clinical and research tool to appropriately classify and measure
 Refractory Inflammatory Arthritis with alignment to routinely used measures.
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117

Refractory Inflammatory Arthritis revised definition and model

118 Introduction

Refractory Disease (RD) in people with rheumatoid arthritis (RA) refers to the 119 persistence of disease activity and symptoms despite treatment with multiple drugs 120 with different mechanisms of action (1), by not achieving low disease activity target 121 after resistance to two or more biologics (2-5). Previous definitions of RD have focused 122 123 on biological underpinnings based mainly on rheumatologists' experiences alone (if definition generation stated) (1), without consideration of wider psychosocial 124 contextual components that need to be incorporated from a multi-disciplinary 125 perspective (6). Therapeutic strategies following a treat-to-target regimen are 126 generally successful in reducing inflammatory markers, however patient-reported 127 outcomes have not similarly improved (7, 8). 128

There is evidence that patients' prefer holistic approaches adopting patient-129 centred care (9) to avoid the misattribution that symptomatology is solely due to 130 inflammation. This absence of adequate management strategies ensures persistent 131 poor patient-reported outcomes. This current project, along with others (2, 5), stems 132 from a Versus Arthritis workshop in 2015 on the topic of RD that highlighted the need 133 for a broader definition, incorporating the patient perspective (10). A key knowledge 134 135 gap identified was differences in patients and clinicians' definitions of RD. The biopsychosocial model of RD is poorly understood and refining the concept could 136 identify novel approaches to adopt a broader perspective to treatment and care. 137

Although current RD research focuses on Rheumatoid Arthritis (RA), there is clear justification for incorporating Polyarticular Juvenile Idiopathic Arthritis (PolyJIA), particularly for those now in adulthood, who despite presenting a RD course are commonly excluded from such research therefore outcomes and impact of disease and treatment are not fully understood and under recognised (1, 11). Since JIA, and

Refractory Inflammatory Arthritis revised definition and model

in particular the Polyarticular subset, are not benign and self-limiting to childhood (12),
it is important and clinically useful to utilise a common language and approach to
classify and treat these patients similarly to other rheumatic diseases seen in adult
rheumatology care (13).

Absence of a systematic approach to identify or evaluate RD means the true 147 impact and underlying mechanisms remain largely unknown (5). The growing number 148 of publications on this topic (1) and European Alliance of Associations for 149 Rheumatology (EULAR) Task Force on the wider concept of Difficult-to-Treat RA (2), 150 highlights the need to identify, consolidate and implement additional components of 151 RD. This could assist identifying patients who may benefit from pharmacological 152 versus non-pharmacological interventions, and address additional strategies, such as 153 coping and self-management. 154

The aim was to explore and refine the definition of Refractory Disease (RD) 155 considering the perspectives of healthcare professionals (HCPs) and patients, explore 156 its meaning and implications, and identify uncertainties about the terminology and 157 components. The primary objective was to reach a revised consensus definition of RD 158 in RA and PolyJIA from across multi-disciplinary HCPs and patients' perspectives. The 159 secondary objective was to assess the feasibility of using the revised definition to 160 identify RIA in a theoretical application, and revise associated outcome measures if 161 necessary. 162

- 163
- 164

165

Refractory Inflammatory Arthritis revised definition and model

167 Materials and Methods

168 **Design**

The current study was designed and set up following the Versus Arthritis workshop (10), comprising of a PhD studentship initiated in 2017. The study involved three phases: 1) Component Development and 2) Delphi Voting (Figure 1). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement guidelines (14) have been adhered to, where appropriate, and checklist for cohort studies included.

175 **Figure 1:** Study Overview

In phase 1, a pool of components was developed based on a multimodal evidence synthesis. We use the term components to refer to specific facets that operationalise RD (e.g. synovitis, joint pain).

In phase 2, a consensus definition of RD was developed using a Delphi approach, by surveying panels of experts to achieve a group agreement or convergence of opinion (15). Components not included in the consensus definition were retained in a broader conceptual model.

In phase 3, a theoretical application of the definition was conducted through ascoping exercise of rheumatology registries and cohorts.

185 **Component Development**

186 Components of RD were identified from: 1) qualitative interviews and focus 187 groups with patients and HCPs (16), 2) systematic review of studies of RD in 188 RA/PolyJIA (1), and 3) review and application of biopsychosocial theories regarding

Refractory Inflammatory Arthritis revised definition and model

chronic illness and persistent symptoms. Firstly, an initial inductive thematic analysis 189 of 25 patient and 32 HCP interviews conducted between August 2018 and April 2019 190 identified 17 components for common experiences of RD and persistent symptoms, 191 whilst an additional seven were patient-specific (including JIA-specific) and four 192 professional-specific (16) (see unpublished thematic map in S1). This qualitative data 193 analysis was part of a larger framework analysis, which involves five steps (17, 18): (i) 194 195 familiarisation with data, (ii) preliminary thematic analysis to develop initial themes (presented here and (16)), with further steps occurring later which were: (iii) application 196 197 of themes to the whole dataset systematically, (iv) reducing data from transcripts into summaries and organising these into a matrix (participants by themes), and (v) 198 identifying patterns and relationships across participants and themes (manuscript in 199 200 preparation). Secondly, a systematic review of existing definitions (1) identified three key elements of RD: 1) treatment, 2) presence or absence of inflammation and 3) 201 symptoms and impact. These elements were used to group the components and a 202 three-part definition was explored. Due to the large number of components identified, 203 and to account for similarities between components, these were grouped thematically 204 into higher level domains (e.g. disease activity, pain). 205

From the interviews and systematic review, it became clear that some factors 206 207 (e.g. reduced mobility) are related to defining RD, whilst others (e.g. social support) are more relevant to describing poor prognostic, perpetuating or protective elements 208 related to the experience of RD. These factors can guide treatment strategies in line 209 with a biopsychosocial formulation (19-21). This is an integrative process that enables 210 consideration of the complex, interacting factors implicated in development of a 211 patient's presenting problems to translate the diagnosis into specific, individualised 212 213 interventions. This formulation has not previously been applied to RD and could help

Refractory Inflammatory Arthritis revised definition and model

holistically define and explain RD drawing from theoretical models such as Adjustment
to Chronic Illness and Illness Perception Models (22, 23) by aligning identified
concepts to established theories and utilising their terminology and descriptions.
These theoretical models outline the individual behavioural, emotional and cognitive
factors involved in adjustment and adaptation to chronic illness related to the return to
equilibrium following critical illness events/stressors.

Findings from these three areas of research were combined during phase 1 to develop an initial 72 components across 12 domains (see S2) for the Delphi phase (24), by mapping these concepts onto currently used measures within Rheumatology (25) such as Musculoskeletal Health Questionnaire (MSK-HQ) (26) and (Child) Health Assessment Questionnaire ((C)HAQ) (27, 28) to increase utility and validity. The specific wording of the components was agreed by the wider study team (HC, SN, HL, CS, KW and EN).

227 Delphi Voting

The Delphi method allows synthesis of the best available information, an 228 anonymous and iterative process of consensus and validation between key 229 feedback stakeholders/end-users, with thereby increasing ownership 230 and engagement (29). Here we used a modified Delphi process through an initial face-to-231 face nominal/expert group (September 2019), followed by two rounds of Delphi 232 surveys online (March-May 2020) (15, 24, 30-32) to vote on preferred terminology and 233 variables that define RD. Specifically, we sought consensus on (i) preferred name, (ii) 234 domains to retain in the definition, and (iii) components to retain within each domain. 235 The process was managed by a non-voting co-ordinator (HC). 236

237

Refractory Inflammatory Arthritis revised definition and model

a) Participants and Sample size

A purposive sampling strategy (33) was employed to identify potential Delphi 239 participants who had experience of RD and/or persistent symptoms in RA/JIA. Three 240 independent inclusion criteria determined who was invited (33): (1) Patients with 241 RA/PolyJIA or HCPs within Rheumatology, (2) involvement with RA/JIA patient 242 243 organisations or (3) recognized academic career in RD or Persistent symptoms in RA/JIA. Participants were contacted via e-mail and invited to participate anonymously 244 online via Qualtrics software (Qualtrics 2020, Provo, UT), to take part in all online 245 rounds of voting, regardless of whether they had participated in the previous round. 246 This was to ensure a wide representation and allow recruitment to target during 247 COVID-19 since many academics and HCPs were redeployed to frontline NHS 248 services during this time (March and May 2020). Written informed consent was 249 obtained prior to participation in each round. 250

There is currently no formal sample size calculation in Delphi processes (15). 251 A pragmatic approach was adopted in line with previous literature (30-32). The 252 absolute minimum sample size agreed was 12 per round, with at least three members 253 per participant group (Rheumatologists, other HCPs, Patients, and Researchers). A 254 target sample size of at least 40 was set for the online surveys based on estimated 255 256 95% confidence intervals (CIs) providing sufficient precision to discriminate between domains rated for inclusion/exclusion from the consensus definition. A total of 89 257 participants were invited to allow for non-response and attrition. 258

b) Data Collection and Analysis

Four different stages of analysis were conducted: 1) Name ranking, 2)
 Treatment/Inflammation cut-off inclusion, 3) Symptoms/ Impact domain inclusion, and

Refractory Inflammatory Arthritis revised definition and model

4) Component importance rating. Firstly, proportions and 95% CIs were calculated to 262 determine the name preference voting. Participants indicated their top three name 263 choices in each round with the choice receiving majority vote in the final round 264 proposed as the final definition name. Secondly, for the treatment and inflammation 265 questions, there was a need to achieve consensus on whether the definition needs to 266 specify distinct cut-offs or include a broader statement (see S3). Options receiving 267 268 most responses in the first round were taken forward to the next round. Thirdly, for each domain participants were asked to rate whether the domain needed inclusion on 269 270 a nine point Likert scale (1='Definitely Not Include' to 9='Definitely Include') (15). In line with previous literature (30-32), a priori level of agreement was required (\geq 70%) 271 rating domains 7-9 for inclusion and 1-3 for exclusion). Mean and 95% CIs were also 272 estimated to allow consideration of the certainty of domain inclusion or exclusion. 273

Finally, for each component, participants were asked to rate how related the 274 component is to assess a) Refractory Arthritis, and b) Disease flare (-3='Highly 275 Unrelated' to 3='Highly Related'), and to provide comments to clarify component 276 meaning (30) (see S3). Inclusion of components in the consensus definition was based 277 on: a) high mean related total scores for Refractory Arthritis, and b) mean difference 278 and effect sizes between ratings for Refractory Arthritis and Disease Flare. This 279 second criterion allowed discriminant validity to be established to ensure selected 280 components appropriately differentiated between these two constructs. Scores within 281 participant groups were also considered to identify differences across groups and 282 ensure that components rated as important by one group, particularly patients and 283 rheumatologists, were not excluded. 284

285 Several exploratory subgroup analyses were undertaken to assess differences 286 across the four different role groups (Patients, Rheumatologists, Other HCPs and

Refractory Inflammatory Arthritis revised definition and model

Researchers), in terms of representation across the different rounds of voting in both 287 those who started and completed all voting, and in ranking and scoring of the 288 symptoms and impact domains for inclusion. To assess whether there were any 289 differences across the different rounds of voting regarding the sociodemographic 290 characteristics such as years of rheumatology experience and adult versus paediatric 291 trained, one-way ANOVAs were conducted for continuous variables and Fishers exact 292 293 tests for categorical variables due to low numbers per category. To assess differences across the clinical role groups (Rheumatologists, Patients and Other Healthcare 294 295 Professionals) in voting on domains for inclusion, simple linear regressions for each domain were conducted with additional tests and contrasts to determine significant 296 variability. 297

The minimum response for each domain was set at \geq 75% (32) and only whole 298 domains could be missing rather than components within domains due to the software 299 used for data collection, further analysis such as mixed-effect models was not required 300 to adjust for missing data. Additional analysis of the related ratings to generate Item-301 level Content Validity Indexes (I-CVI) (34) was conducted to ensure the final definition 302 is composed of an appropriate components to adequately represent the construct of 303 interest whilst also considering inter-rater agreement to reflect consensus. The final 304 chosen components were then again initially mapped onto to routinely used measures 305 identified from literature searching (35, 36). 306

Theoretical Definition Validation

A theoretical validation through literature scoping of worldwide RA and JIA registries/cohorts was undertaken (between October 2022 and February 2023) to highlight what components and domains of the definition could be utilised, and to identify alternative measures if possible. The feasibility and application of using the

Refractory Inflammatory Arthritis revised definition and model

identified outcome measures or data points to identify RIA was then explored using 312 frequencies. Websites of relevant rheumatology organisations were screened for 313 details of relevant registries and/or cohorts with PROMs for RA and JIA. This was 314 supplemented by internet searches of rheumatology registries and cohorts to identify 315 details of the data collected in the registries which was extracted from study-specific 316 websites or publications. This initial searching uncovered summary studies that have 317 318 a similar scoping aim and captured some of the required data (36-39). A summary table was produced to highlight the data captured across the included registries and 319 320 cohort studies (36).

321 Patient and Public Involvement

Patients were involved in the design, conduct, reporting, and dissemination of this research, in which AB, CS and KW have been integral at all stages as Patient Research Partners. Numerous others were involved in the design of this project which evolved through various stages of involvement with people with RA and PolyJIA. Both diagnoses were included because early patient and public involvement work revealed that RD is a problem across both age and disease groups.

328 Results

329 Sample characteristics

Across the three rounds,106 votes were cast in this Delphi study as seen in Table 1. Due to anonymity, the total number of unique participants or number of rounds each participant voted in cannot be determined. There were no differences in participant characteristics (e.g. Rheumatology experience or diversity of roles) between each round for those that completed, nor between those who dropped out (n=3 each online round) (see S4). In Round One, duplicate data for two responses

Refractory Inflammatory Arthritis revised definition and model

336	(e.g. started survey on one device then continued on another) was removed, otherwise
337	attrition occurred such that domain completion rates were between 90-100%, therefore
338	meeting the pre-determined minimum response rate. In Round Two, the attrition
339	occurred after the name ranking questions, with otherwise complete data.
340	
341	
342	
343	
344	
345	
346	
347	
348	
349	
350	
351	
352	
353	
354	
355	

Refractory Inflammatory Arthritis revised definition and model

356 **Table 1:** Characteristics of Delphi Voters (n=106)

	Face-to-Face	Online Delphi	Online Delph
	Nominal Group	Round One	Round Two
	(N = 13)	(N = 40)	(N = 53)
Role, n (%) [†]			
Rheumatologist	5 (38.5%)	11 (27.5%)	17 (32.1%)
Nurse	1 (7.7%)	4 (10%)	3 (5.7%)
GP	1 (7.7%)	3 (7.5%)	3 (5.7%)
Pharmacist	0	1 (2.5%)	3 (5.7%)
Psychologist	0	2 (5%)	3 (5.7%)
Podiatrist	0	1 (2.5%)	1 (1.9%)
Physiotherapist	0	3 (7.5%)	5 (9.4%)
Occupational Therapist	0	2 (5%)	4 (7.6%)
Patient Representatives	3 (23.1%)	8 (20%)	10 (18.9%)
Researcher*	3 (23.1%)	4 (10%)	3 (5.7%)
Social Worker	0	1 (2.5%)	1 (1.9%)
Number of years' experience			
in Rheumatology, mean (SD)			
Professionals	15.10 (12.07)	15.59 (11.30)	16.07 (8.62)
Patients	21.33 (16.29)	25.62 (14.17)	28 (12.29)
Predominantly			
trained/worked [‡] , n (%)			
Adult	9 (90%)	20 (62.5%)	29 (67.4%)
Paediatric	1 (10%)	6 (18.75%)	7 (16.3%)
Both	0	6 (18.75%)	7 (16.3%)
Received specific MSK			
training [‡] , n (%)			
Yes	6 (60%)	24 (75%)	32 (76.7%)
No	4 (40%)	8 (25%)	10 (23.3%)

[†]Although participants were allowed to select multiple roles, the main role is reported here.
 [‡]Professional roles only were reported. *Researchers covered the following disciplines:
 Radiology, Psychology, Medical Sociology, Rheumatology and Health Services, Statistics and
 Epidemiology.

Refractory Inflammatory Arthritis revised definition and model

361 Name Preference Voting

During the nominal group workshop (one missing voter due to late arrival), ten 362 terms were voted on for the name of the definition, of which RD, Persistent Disease 363 and Treatment Resistant were the most popular (see S5). Moreover, participants 364 suggested that the terminology should include Part A and Part B elements to form 365 366 different name iterations to be voted on subsequently, with the following additions: 'Ongoing', 'Inflammatory Arthritis', 'Syndrome', 'Inflammation' and 'Symptoms'. 367 Consequently, the top three preferences from Round One online voting were 368 combined to create nine names involving all combinations of the label (e.g. refractory, 369 resistant) and target (e.g. inflammatory arthritis, disease), which participants were 370 asked to again select their top three in Round Two (see S5). Refractory Inflammatory 371 Arthritis received the majority vote (25% of votes), followed by Persistent Inflammatory 372 Arthritis (19% of votes). There was slight disparity in the top preference between 373 Patients and the other three groups as Persistent Inflammatory Arthritis received 374 21.6% of the votes by Patients whilst both RIA and RD received 15%. 375

376 Definition of Refractory Inflammatory Arthritis


Based on the Delphi process (detailed below), a consensus definition for RIA 377 is proposed in Table 2. This three-part definition covers the core elements identified in 378 phase 1: 1) treatment, 2) inflammation presence (Persistent Inflammation) or absence 379 (Persistent Symptoms) and 3) symptoms and impact, which comprises 18 components 380 across 6 domains to capture the presentation and experience of RIA. To identify a 381 patient as having RIA, at least one component from each part 1-3 need to be met, and 382 initial suggestions for assessment for each component included 20 data points (see 383 S10) such as (C)HAQ (27, 28), MSK-HQ (26), Consultation / Joint Examination / 384

Refractory Inflammatory Arthritis revised definition and model

385	Clinical Notes (40) and EuroQol 5-Dimensions (EQ5D) (41). These are based on
386	commonly used measures in paediatric and adult rheumatology clinical cohorts and
387	registers (35, 36), with suggested cut-offs or scoring direction on continuous measures
388	and were explored further in the theoretical validation exercise.
389	
390	
391	
392	
393	
394	
395	
396	
397	
398	
399	
400	
401	
402	
403	
404	

Refractory Inflammatory Arthritis revised definition and model

405 **Table 2:** Revised consensus definition of Refractory Inflammatory Arthritis



Refractory Inflammatory Arthritis revised definition and model

An overview of the phases of definition development including refinements and 407 voting results during Delphi rounds are presented in S6. Nominal group attendees 408 agreed all 12 domains (85-100%) to be included in the next stage of voting. All 409 domains were voted as related to RD, with Pain, DMARD Experiences, Joint Activity 410 and Co-morbidities rated the most highly, whilst Poor Quality Sleep, Steroid Use and 411 412 Dependency and Social Functioning and Quality of Life were rated the lowest. 413 Discussion included the addition of Healthcare Utilisation (eight components) to the Steroids domain, with refinements/additions to eight other components e.g. sex, 414 415 benefits, variability, assessment of feet and removal of one component ("unable to relax easily"). They also stated the importance of investigating other undiagnosed 416 underlying reasons for these symptoms in case these treatable causes are driving 417 suspected RD e.g. thyroid issues causing fatigue. Further discussions with the study 418 team and Health Psychology Group at KCL took the final total count of components 419 identified for voting to be 73 across 10 domains as the three Functioning and Quality 420 of Life Domains were condensed into one domain (see S2). 421

In Round One online voting, for Parts One and Two regarding Treatment and 422 Inflammation factors, the consensus was for these to be kept broad (65-70%) as 423 originally proposed rather than specifying fixed cut-offs (Tables 2 and 3). As seen in 424 Figure 2, seven domains in Round One met consensus criteria for inclusion (≥70%) 425 rating the domain between 7-9 for inclusion on the 1-9 scale) for Part 3 Symptoms and 426 Impact (see S7 for data and decisions). Of these, three were clearly above this 427 inclusion threshold, whilst the remaining four indicate uncertainty as to the 428 generalisability of inference. The remaining three domains did not reach agreement 429 whether to include or exclude, and when converted into rankings were consistently the 430 lowest across the different role groups (see S8). Rheumatologists and Other 431

Refractory Inflammatory Arthritis revised definition and model

Healthcare Professionals ranked Joint Activity highest, then Stiffness and Disease
Activity in their top three. Whereas Patients ranked Disease Activity and Fatigue jointly
highest with Pain third as their top three, therefore more symptom focussed.
Researchers ranked Disease Activity highest then Pain and Functioning and Quality
of Life as joint second in their top three.

437 **Figure 2:** Round One Domains and Round Two Components Inclusion

Regression analyses revealed no differences in mean include scores across 438 439 the training specialties (Adult vs Paediatric vs Both), however there were some subtleties in the domains reaching criteria for inclusion. Analyses highlighted the 440 different priorities and considerations for HCPs with paediatric versus adult patients. 441 442 For Paediatric professionals, Fatigue (66.67%) and DMARD experiences (33.33%) did not reach inclusion criteria, with Pain (66.67%) and Functioning and Quality of Life 443 (66.67%) also falling short for those trained in Both. There was greater variability in 444 responses for the group that had received both Adult and Paediatric training, who were 445 encompassed heterogenous population that mixture of Researchers, 446 а Rheumatologists, a Physiotherapist and a GP. 447

From Round One voting, 30 components from the seven included domains 448 were retained based on mean related scores and the difference with flare, and I-CVI 449 450 scores. The core study team (HC, SN, HL) then discussed and prioritised those with higher mean related score, followed by those with medium-to-large difference whilst 451 considering the I-CVI and any free text comments regarding modification and 452 clarification (see S9 & S10). This resulted in final data driven selection of 16 453 components, through combining two domains (Joint Activity and Stiffness into Joint 454 Involvement) and combining some components (e.g. Pain during the day and Pain 455 during the night combined into Pain during day and/or night). 456

Refractory Inflammatory Arthritis revised definition and model

Thirteen components, not achieving consensus in round one, were taken 457 forward to Round Two (see S2): nine components from Sleep. Co-morbidities and 458 Wider Involvement Outside of Joints and Healthcare/Medication Utilisation and 459 exploration of four exclusion criteria from components voted in Round One as highly 460 unrelated. From Round Two, only two components out of the 13 voted upon reached 461 the required criteria for inclusion (see S7 and Figure 2), taking the total number of 462 463 components achieving consensus for inclusion to 18. The core research team decided not to hold a third round of online voting as only three components had not achieved 464 465 consensus for inclusion or exclusion. Given each included domain consisted of at least two components, these three components were excluded from the definition. 466

467 Refractory Inflammatory Arthritis (RIA) Conceptual Model

A wider conceptual model was generated by the core research team to allow 468 for consideration of the relationship between the domains and components excluded 469 from the consensus definition and RIA, based on the Phase 1 development work (1, 470 16). The concepts and examples given here are based on findings from the systematic 471 review highlighting the role of other contributing factors such as Serology and fixed 472 disease factors such as disease duration (1) and qualitative work on patients' and 473 HCP' experiences of RIA (16) (see S1) such as social support and independence 474 475 which included elements such as adjustment, resilience and illness/treatment beliefs which align with general theories of perceptions and adjustment to long-term illness. 476 This followed a Biopsychosocial Formulation (19, 20) (see Figure 3), with the Definition 477 of RIA with Persistent Symptoms or Inflammation at the core, surrounded by 478 Predisposing, Poor Prognostic, Perpetuating and Protective factors. 479

480 **Figure 3:** Proposed Conceptual Model of Refractory Inflammatory Arthritis

Refractory Inflammatory Arthritis revised definition and model

Some of the Precipitating factors are the same to RA/PolyJIA generally, whilst 481 Poor Prognostic factors suggest some mechanisms identified for those that then lead 482 to have a more refractory course, which therefore cannot be modified. However, 483 building on these symptoms and impact are the Protective and Perpetuation factors 484 that describe some of the biopsychosocial mechanisms underpinning why some 485 patients may experience negative and worsening impact of RIA (Perpetuating) on their 486 487 daily lives whilst others appear to manage and live with reduced impact (Protective), despite experiencing RIA with Persistent Symptoms or Inflammation. The allocation of 488 489 factors is individual and based on the Impact Triad (42), which includes the patient's perceived severity, importance and ability to self-manage/cope with the factor or 490 symptom to determine patient priorities from the level of perceived impact. The 491 Protective and Perpetuating factors can be modified and targeted to reduce disease 492 impact and improve quality of life. This conceptual model allows for the identification 493 of potential risk factors and interventional targets that Rheumatologists and other 494 HCPs can consider as part of the shared decision-making process of deciding which 495 treatments may be most appropriate for patient. 496

497 **Theoretical Definition Validation**

A total of 61 registries/cohorts were identified across 63 publications in the scoping exercise (36, 37, 43-104) (detailed in S11), of which most were RA (n=43, 70.5%) and in Europe (n=39, 63.9%). Across the registries/cohorts identified, the four most complete components from the 20 initial data points (see S12) were Joint Count (n=61, 100%), ESR/CRP (n=60, 98%), (C)HAQ (n=58, 95%) and Clinical notes/information (n=55, 90%) with the four most missing components being the Work and Social Adjustment Scale (WSAS), RA Distress Scale (RADS), and Bristol RA

Refractory Inflammatory Arthritis revised definition and model

505 Fatigue (BRAF) which were not collected in any, and MSK-HQ was only collected in 506 one (59).

The registries/cohorts contained between 6-15 (27-68%) of the proposed data 507 components (out of 20). For each part of the definition, the following could be applied: 508 Part One: Treatment (82%), Part Two: Inflammation (100%), Part Three: Symptoms 509 510 and Impact (100%), and for each subdomain (as only one component is necessary): 3.1) Disease Activity (100%), 3.2) Joint Involvement (100%), 3.3) Pain (87%), 3.4) 511 Fatigue (26%), 3.5) Functioning and Quality of Life (98%), and 3.6) DMARD 512 Experiences (92%). Therefore, the RIA definition could be applied to 82% of the 513 identified registries/cohorts. Several appropriate substitutions were used in these 514 studies of which the most common relevant measures that could be substituted were 515 the Patient Global VAS (PGA) (n=40) and SF-36 (n=19). By adding these two 516 measures, the following increases in the application of the definition for subdomains 517 of Part Three were found to be: 3.3) Pain (98%) and 3.4) Fatigue (93%), which is the 518 most marked increase. 519

This scoping exercise established the theoretical feasibility of applying the RIA 520 definition by highlighting which data points are collected or missing. None collected all 521 the initial 20 measures, although the RIA definition as it is initially proposed could be 522 applied to 50 registries/cohorts (82%) if only one item from each part is satisfied and 523 to 10 registries/cohorts (16%) if an item from each subdomain of Part Three is met to 524 identify RIA. With the addition of PGA and SF-36, 45 registries/cohorts (74%) capture 525 one item from each of the six subdomains of Part Three increasing its utility and 526 coverage of all subdomains as discussed below for symptom-based stratification. 527 Therefore following the scoping exercise, SF-36 and PGA was included in the 528 assessments mapped on to the RIA definition as seen in Table 3, as general measures 529

Refractory Inflammatory Arthritis revised definition and model

- to substitute for missing disease-specific measures (105, 106). Disease and symptom
- specific measures, e.g. Pain VAS rather than PGA, need to be prioritized by assessors
- 532 but to increase application and utility, relevant generic measures may be appropriate
- 533 alternatives.

Table 3: Assessments mapped onto Refractory Inflammatory Arthritis definition

RIA	Definition	Assessment Methods (including cut-offs)
Part	1: Treatment	Treatment History (≥1 csDMARDs, and ≥1 anti-TNF/b/tsDMARDs) (40)
Part	2: Inflammation	Abnormal/Raised Inflammatory markers (ESR / CRP based on the local laboratory standards or ESR
Symptoms and Impact		>10 and CRP >3 based on mean values) (40, 107)
		Physical examination (T/S/A/LJC) ≥1 (40, 108)
		Imaging of Synovial Inflammation (Ultrasound or MRI) (40)
	1. Disease Activity	Clinical notes / Consultation (or mention of extra-articular manifestations etc) / Medical and Treatment
		History (40) DAS28 >3.2 (109) or SDAI >11 (110)
		RAID (scoring higher on Q5) (111)
	2. <u>Joint</u>	MSK-HQ (scoring 0-2 on Q1 and/or 2) (26)
	Involvement	Consultation / Physical examination (TJC/SJC) ≥1 / Clinical Notes (40, 108)
		Stiffness Assessment (>30 minutes duration) (112)
		Imaging of Damage/Erosions Score (Radiographs) (40)
Sym	3. <u>Pain</u>	MSK-HQ (scoring 0-2 on Q1 and/or 2) (26)
: : : :		Pain VAS >3.5 (113) or PGA ≥3 (106)
Part 3:		EQ5D (scoring 2 or 3 on Q4) (41)
		RAID (scoring higher on Q1) (111)
		Pain Scale of SF-36 (average of recoded items 21 and 22) (105)

Refractory Inflammatory Arthritis revised definition and model

RIA Definition		nition	Assessment Methods (including cut-offs)
	4.	Fatigue	BRAF (Higher total score and on items) (114)
			Fatigue VAS >2.0 (115) or PGA ≥3 (106)
			MSK-HQ (scoring 0-2 on Q10) (26)
			RAID (scoring higher on Q3) (111)
			Vitality Scale of SF-36 (average of recoded items 23, 27, 29 and 31) (105)
Part 3: Symptoms and Impact	5.	Functioning and	(C)HAQ (≥1 total score to represent moderate-to-severe disability) (116)
		Quality of Life	EQ5D (scoring 2 or 3 on Q1-3 and Q5) (41)
			Physical Functioning Scale of SF-36 (average of recoded items 3-12) (105)
			Role Limitations Scale of SF-36 (average of recoded items 13-19) (105)
			Social Functioning Scale of SF-36 (average of recoded items 20 and 32) (105)
			WSAS (higher total score and on items 1-4) (117)
			MSK-HQ (scoring 0-2 on Q3-7 and Q11) (26)
urt 3			RAID (scoring higher on Q2 and Q6) (111)
Ра			RADS (118)
			Emotional wellbeing scale of SF-36 (average of recoded items 24-26, 28, 30) (105) or SF-36 (scoring
			≤38 on the Mental Component Subscale) (66)
			Consultation (40)
	6.	<u>cs/b/tsDMARD</u>	Clinical notes / Treatment and DAS28 History / Consultation (or mention of steroid use and reasons for
		Experiences	DMARD changes) (40)

Please Note: DAS28: Disease Activity Score 28 joint count, SDAI: Simplified Disease Activity Index, RAID: Rheumatoid Arthritis Impact of Disease, (C)HAQ: Child or Adult Health Assessment Questionnaire, MSK-HQ: Musculoskeletal Health Questionnaire, VAS: Visual Analogue Scale, EQ5D: EuroQol 5-Dimensions, BRAF: Bristol RA Fatigue Scale, WSAS: Work and Social Adjustment Scale, RADS: Rheumatoid Arthritis Distress Scale

Refractory Inflammatory Arthritis revised definition and model

1 Discussion

This study presents the development of a consensus definition for Refractory 2 Inflammatory Arthritis (RIA) with Persistent Symptoms or Inflammation across multi-3 disciplinary HCPs and patients, in line with the study aim and objectives. This three-4 part definition covers core elements of treatment, presence or absence of 5 6 inflammation, and symptoms and impact, including: 1) Disease Activity, 2) Joint Involvement, 3) Pain, 4) Fatigue, 5) Functioning and Quality of Life, and 6) DMARD 7 Experiences. This captures the multi-faceted presentation and experience of RIA in 8 RA and PolyJIA populations covering biological and psychological symptoms. This 9 work independently validated and supports the growing body of evidence to 10 understand and refine the concept of Refractory Disease (RD), notably the EULAR 11 Difficult-to-Treat Task Force and others (2, 4, 5, 119-121). It is worth noting that the 12 current study was designed and set up in 2017, as part of a Health Psychology PhD 13 programme of research before publication of the EULAR Difficult-to-Treat Task Force 14 work. These parallel bodies of work have reached similar conclusions that a broader 15 definition needs to include treatment, symptoms (including inflammation) and impact 16 as part of the RIA concept, however these have been more generally stated in the 17 EULAR definition (2, 120). 18

Here we suggest an extension to this general criterion recently proposed by detailing a three-part definition identified as important to both patients and multidisciplinary HCPs with 18 specific components within 6 domains that can be operationalised. Additionally, our definition has been derived through a different evidence synthesis approach, e.g. systematic review, qualitative interviews, application of biopsychosocial theory and Delphi consensus voting, which is a different, more methodologically rigorous approach than a survey, scoping literature

Refractory Inflammatory Arthritis revised definition and model

review and agreement process (consensus not defined) (2). Another distinguishing 26 feature of this study is participation of a larger number of patients, multi-disciplinary 27 professionals from nine relevant specialties and researchers across both adult and 28 paediatric services to include PolyJIA within this refractory concept, compared to the 29 Difficult-To-Treat Taskforce which consisted of rheumatologists predominantly, two 30 patient partners, one health professional (not defined), one psychologist, one 31 32 pharmacist and one occupational therapist (2). Another feature was the selection of the name for the definition, which fits with the common use of the term Refractory in 33 34 the literature (1), and the distinction with Difficult-To-Treat Disease (120).

For Paediatric professionals, Fatigue and DMARD experiences did not reach 35 inclusion criteria. However, it is important to bear in mind the lower sample sizes for 36 the Paediatric and Both groups compared to the Adult sample, therefore no firm 37 conclusions can be drawn to suggest these domains and their components would 38 39 need to be removed for a paediatric specific definition. Given there were no significant differences in the domain means, it seems that the proposed definition based on the 40 whole group scores may be appropriate for use in the paediatric PolyJIA population 41 as well, and requires further exploration. This study has shown that it is feasible to 42 include both adult and paediatric professionals and patients. Given the relative rarity 43 of JIA and those specialising in paediatric and adolescent rheumatology, the use of a 44 transdiagnostic approach in future research can be advantageous. 45

This scoping exercise established the feasibility of applying the revised definition of RIA in line with the second objective to 61 identified datasets, which found that the definition has good utility. The RIA definition could be applied to 82% of datasets and has been revised to include suggestions for 22 data points that are routinely collected in clinical practice and research studies. The main outcome that

Refractory Inflammatory Arthritis revised definition and model

51 limited the application of the definition was Treatment History, as only a single item was required for Part One whereas for Parts Two and Three there were multiple 52 alternatives. This lack of reporting for treatment history would also be a limitation for 53 the other definitions that are based on multiple bDMARDs (2, 4). The findings fit well 54 with a systematic review of outcome measures used in 88 RA registries and long-term 55 observational studies where disease activity (mainly DAS28) and physical functioning 56 57 (mainly HAQ) was consistently recorded in included studies whilst there was heterogeneity in the patient-centred outcomes for symptom burden and psychosocial 58 59 ramifications (2, 122). This type of validation was not conducted with the original definition of Refractory Disease (3), nor to the same degree with the most recent 60 definitions (2). 61

Unlike previous definitions (1, 2), the development of the new RIA definition 62 presented in this paper included consideration of content and discriminant validity 63 indicators (I-CVI and mean difference with flare) and therefore provides a tool to 64 appropriately identify and measure RIA, alongside a conceptual model of related 65 factors. This RIA definition could serve as a clinical or research checklist with the 66 components aligned to routinely used measures (35, 36), as listed in Table 3 to enable 67 identification of aspects requiring further support e.g. low HAQ indicating issues with 68 functioning and quality of life (Domain 5) could prompt a referral to Occupational and 69 Physiotherapies (8). The use of cut-offs increase outcome interpretability, making the 70 71 RIA definition more meaningful and applicable in both in clinical practice and research, by allowing data to be compared and pooled (123). A criticism of the Difficult-to-treat 72 definition (2) is the subjective character of the third criterion which meant not all 73 elements could be applied to a dataset as it was deemed too subjective to extract from 74 75 the available data (124). Messelink and colleagues also highlighted that whether "the

Refractory Inflammatory Arthritis revised definition and model

management of patients is perceived as problematic" will most often not be routinely
noted in health records and stated this lack of clarity and objectivity to be a key
challenge in future research using the Difficult-to-treat definition (2).

Within the RIA model presented here, Protective and Perpetuating Factors 79 suggest some of the underlying biopsychosocial mechanisms that may explain why 80 some patients experience negative and worsening impact of RIA in their lives 81 82 (Perpetuating) whilst others have minimal or less impact despite experiencing RIA (Protective). By identifying the specific Protective and Perpetuating factors deemed to 83 84 have an impact through biopsychosocial formulation for each patient (19, 20, 42), it may be possible to address these wider clinical and sociodemographic factors that 85 contribute to non-response to treatment, which is important to identify those requiring 86 additional non-pharmacological support from a multi-disciplinary team (6, 8, 21, 121). 87 This fits with subsequent EULAR work which identified multiple contributing factors, a 88 high burden of disease and the heterogeneity of Difficult-To-Treat RA (125), 89 suggesting that these factors should be identified in daily practice in order to tailor 90 therapeutic strategies further to the individual patient with the RIA model providing 91 such a framework. 92

Several limitations and potential bias within the current study should be 93 94 discussed. It would have been useful to have a patient and clinician included in the core study team discussions during the delphi voting iterations following nominal group 95 discussions however this process was data driven with little subjective decision 96 making made by the researchers involved. Since most domains met pre-defined 97 inclusion criteria in the first round, the process was less iterative than previous Delphi 98 studies (31, 32), without continuous re-voting on the same components and due to 99 100 anonymity the team was unable to provide individualised feedback to voters. This may

Refractory Inflammatory Arthritis revised definition and model

be a consequence of online data collection, rather than a face-to-face meeting with 101 further deliberation. However, the completion of an online questionnaire enabled a 102 larger number of participants to take part, specifically during the first COVID-19 wave. 103 There was a predominant bias towards participants from the UK followed by Europe 104 and caution is required for applicability of this definition in other countries. This project 105 determined a preliminary definition of RIA, requiring further validation to explore 106 107 staging within the definition to account for severity and differences between conditions and countries. The refinement could be achieved through assessment of retrospective 108 109 cohorts and datasets from the UK, followed by different global cohorts.

110 Conclusion

111 Within Rheumatology, parallel bodies of work have reached similar conclusions regarding the broadening of the Refractory or the wider Difficult-to-Treat concept. The 112 authors provide a different angle to define, measure, and conceptualise Refractory 113 Inflammatory Arthritis (RIA), using health psychology theory across PolyJIA and RA 114 with the input of patients, rheumatologists, and multi-disciplinary HCPs. The multi-115 factorial definition and model proposed can help to identify patients experiencing RIA 116 where inflammation and/or symptoms persist despite treatment and allow for the 117 consideration of wider contextual factors that may not be targeted by pharmacological 118 119 treatments. Future work could explore the application and validity of the RIA definition in other Rheumatic Musculoskeletal Diseases, both adult and juvenile variations. 120 Appropriate adult and paediatric measures have been proposed to measure RIA (25), 121 122 which require further validation to assess practicality and feasibility, and could initiate development of classification criteria. 123

124

Refractory Inflammatory Arthritis revised definition and model

Acknowledgements: Thank you to all the patients and healthcare professionals that 125 took part in the Delphi voting and to the Refractory Delphi Nominal Group which 126 comprised of Ailsa Bosworth, Sam Norton, Heidi Lempp, Katie Bechman, Wendy 127 Olsder, Di Skingle, Flora McErlane, Louise Parker, Elena Nikiphorou, Lianne Kearsley-128 Fleet, Simon Black, Adam Young, and Kevin Davies. Finally, thank to you to Nora Ng, 129 James Galloway, Ian Scott, Debajit Sen, and Rachel Tattersall for support and help 130 131 recruiting to the qualitative study. For the purposes of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Accepted Author 132 133 Manuscript version arising from this submission.

134

135 Supplementary Material Legends (11)

Supplementary Figure S1: Key components of Refractory Disease and Persistent

137 Symptoms identified by Patients and Rheumatologists during Qualitative Interviews.

138 **Supplementary Data S2:** Lists of Components and Domains presented during a)

139 Nominal Group, b) Round One Online Voting, and c) Round Two Online Voting

140 **Supplementary Data S3:** Example of Delphi Voting Questions (Round One Online)

141 Supplementary Figure S4: Analysis of Participants across Delphi Rounds

Supplementary Data S5: Options for Name preference voting with Proportions and
95% Confidence Intervals

144 **Supplementary Figure S6:** Overview of Definition Development and Refinement

Supplementary Tables S7: Statistics for Round One and Two Components
 Considered for Definition

147 Supplementary Figure S8: Round One Rankings of Domains by Role Group

Refractory Inflammatory Arthritis revised definition and model

- 148 **Supplementary Data S9:** Refractory Inflammatory Arthritis Definition Components
- 149 Statistics
- 150 **Supplementary Figure S10:** Example selection of components for inclusion or
- 151 exclusion from included domain
- 152 **Supplementary Table S11**: Assessments initially mapped onto Refractory
- 153 Inflammatory Arthritis definition
- 154 **Supplementary Tables S12:** A) Data capture and synthesis of measures used in the
- 155 RIA definition across RA/JIA Biologic registries/cohort (Location, Condition and Parts
- 156 One and Two). B) Data capture and synthesis of measures used in the RIA definition
- across RA/JIA Biologic registries/cohort (Part Three)
- 158
- 159

References

 Chaplin H, Carpenter L, Raz A, Nikiphorou E, Lempp H, Norton S.
 Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review. Rheumatology.
 2021;60(8):3540-52.
 Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, van der Goes

- MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases. 2020;80:31-5.
- 167 3. Polido-Pereira J, Vieira-Sousa E, Fonseca JE. Rheumatoid arthritis: what is 168 refractory disease and how to manage it? Autoimmun Rev. 2011;10(11):707-13.
- Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, et al.
 Biologic refractory disease in rheumatoid arthritis: results from the British Society for
 Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis.
- 172 2018;77(10):1405-12.
- 5. Buch MH. Defining refractory rheumatoid arthritis. Annals of the RheumaticDiseases. 2018;77(7):966-9.
- 175 6. Zembrzuska H, Kumar B. Further Considerations of the Need for Integrated
 176 Mental Health Treatment in Rheumatoid Arthritis Patients: Comment on the Review
 177 by Matcham et al. Arthritis & Rheumatology. 2019;71(6):1024-5.
- 178 7. Carpenter L, Nikiphorou E, Kiely PDW, Walsh DA, Young A, Norton S.
- 179 Secular changes in the progression of clinical markers and patient-reported
- outcomes in early rheumatoid arthritis. Rheumatology. 2020;59(9):2381-91.
- Schoemaker CG, de Wit MPT. Treat-to-Target From the Patient Perspective
 Is Bowling for a Perfect Strike. Arthritis & Rheumatology. 2021;73(1):9-11.

Refractory Inflammatory Arthritis revised definition and model

183	9. Radner H, Yoshida K, Frits M, Iannaccone C, Shadick NA, Weinblatt M, et al.			
184				
185	patients initiating disease-modifying anti-rheumatic drugs. Rheumatology.			
186	2015;54(11):2076-84.			
187	10. Young A. Minutes from ARUK clinical study group refractory disease			
188	workshop: Prevalence of refractory disease in the UK. 2015.			
189	11. Barbara Ansell National Network for Adolescent and young adult			
190	Rheumatology (BANNAR). BANNAR statement of understanding of current clinical			
191	practice for biologic and biosimilar use in JIA in the UK. 2017.			
192	12. Armon K. Outcomes for juvenile idiopathic arthritis. Paediatrics and Child			
193	Health. 2018;28(2):64-72.			
194	13. Fernandes S, Gomes JAM, Gomes SM, Martins F. Juvenile idiopathic			
195	arthritis: the transition to adulthood. Pediatr Rheumatol Online J. 2014;12(Suppl			
196	1):P193-P.			
197	14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke			
198	JP. The Strengthening the Reporting of Observational Studies in Epidemiology			
199	(STROBE) statement: guidelines for reporting observational studies. Lancet.			
200	2007;370(9596):1453-7.			
201	15. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi			
202	techniques. International journal of clinical pharmacy. 2016;38(3):655-62.			
203	16. Chaplin H, Verhey I, Ng N, Galloway J, Scott I, Sen D, et al. AB0372			
204	Exploring Refractory Disease & Persistent Symptoms in RA/PolyJIA despite			
205	bDMARDS: Patient & Professional Experiences. Annals of the Rheumatic Diseases.			
206	2019;78(Suppl 2):1646			
207	17. Leal I, Engebretson J, Cohen L, Rodriguez A, Wangyal T, Lopez G, et al. Experiences of paradox: a qualitative analysis of living with cancer using a			
208	framework approach. Psycho-Oncology. 2015;24(2):138-46.			
209 210	18. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In:			
210	Bryman A, Burgess RG, editors. Analyzing Qualitative Data: Routledge; 1994.			
211	19. Jellinek MS, McDermott JF. Formulation: Putting the Diagnosis Into a			
212	Therapeutic Context and Treatment Plan. Journal of the American Academy of Child			
213	& Adolescent Psychiatry. 2004;43(7):913-6.			
215	20. Winters NC, Hanson G, Stoyanova V. The case formulation in child and			
216	adolescent psychiatry. Child and adolescent psychiatric clinics of North America.			
217	2007;16(1):111-32, ix.			
218	21. Carroll S, Moon Z, Hudson J, Hulme K, Moss-Morris R. An Evidence-Based			
219	Theory of Psychological Adjustment to Long-Term Physical Health Conditions:			
220	Applications in Clinical Practice. Psychosomatic Medicine. 2022;84(5):547-59.			
221	22. Leventhal H, Meyer U, Nerenz U. The common sense model of illness			
222	danger. In: Rachman S, editor. Medical psychology. 2. New York: Pergamon; 1980.			
223	p. 7–30.			
224	23. Moss-Morris R. Adjusting to chronic illness: time for a unified theory. Br J			
225	Health Psychol. 2013;18(4):681-6.			
226	24. Fernández-Ávila DG, Rojas MX, Rosselli D. The Delphi method in			
227	rheumatology research: are we doing it right? Revista Colombiana de Reumatología			
228	(English Edition). 2020;27(3):177-89.			
229	25. Hannan M, Katz PPE. Patient Outcomes in Rheumatology, 2020 A Review of			
230	Measures [Special Issue]. Arthritis Care & Research. 2020;72(S10):1-749.			
231	26. Hill JC, Kang S, Benedetto E, Myers H, Blackburn S, Smith S, et al.			
232	Development and initial cohort validation of the Arthritis Research UK			

Refractory Inflammatory Arthritis revised definition and model

Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal 233 care pathways. BMJ open. 2016;6(8). 234 Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome 27. 235 in arthritis. Arthritis Rheum. 1980;23(2):137-45. 236 28. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status 237 in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37(12):1761-9. 238 29. Halcomb E, Davidson P, Hardaker L. Using the consensus development 239 conference method in healthcare research. Nurse Res. 2008;16(1):56-71. 240 Maher TM, Whyte MK, Hoyles RK, Parfrey H, Ochiai Y, Mathieson N, et al. 241 30. Development of a Consensus Statement for the Definition, Diagnosis, and Treatment 242 of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi 243 Technique. Adv Ther. 2015;32(10):929-43. 244 245 31. Weerdesteijn KHN, Schaafsma FG, van der Beek AJ, Anema JR. Limitations 246 to Work-Related Functioning of People with Persistent "Medically Unexplained" Physical Symptoms: A Modified Delphi Study Among Physicians. J Occup Rehabil. 247 2017;27(3):434-44. 248 249 32. McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, et al. Development of a consensus core dataset in juvenile dermatomyositis for clinical 250 use to inform research. Annals of the Rheumatic Diseases. 2018;77(2):241-50. 251 33. Diaz-Ledezma C, Higuera CA, Parvizi J. Success After Treatment of 252 Periprosthetic Joint Infection: A Delphi-based International Multidisciplinary 253 254 Consensus. Clinical Orthopaedics and Related Research®. 2013;471(7):2374-82. 255 34. Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Research in nursing & health. 256 2007;30(4):459-67. 257 Radner H, Dixon W, Hyrich K, Askling J. Consistency and Utility of Data Items 258 35. 259 Across European Rheumatoid Arthritis Clinical Cohorts and Registers. Arthritis Care & Research. 2015;67(9):1219-29. 260 Beukelman T, Anink J, Berntson L, Duffy C, Ellis JA, Glerup M, et al. A survey 261 36. of national and multi-national registries and cohort studies in juvenile idiopathic 262 arthritis: challenges and opportunities. Pediatric Rheumatology. 2017:15(1):31. 263 37. Hiligsmann M, Rademacher S, Kaal KJ, Bansback N, Harrison M. The use of 264 routinely collected patient-reported outcome measures in rheumatoid arthritis. 265 Seminars in Arthritis and Rheumatism. 2018;48(3):357-66. 266 Young A. What have we learnt from early rheumatoid arthritis cohorts? Best 38. 267 268 Practice & Research Clinical Rheumatology. 2009;23(1):3-12. Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, et al. 39. 269 Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 270 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration. 271 Annals of the Rheumatic Diseases. 2022;81(10):1358-66. 272 Watts RA, Conaghan PG, Denton C, Foster HE, Isaacs J, Müller-Ladner U. 273 40. Oxford Textbook of Rheumatology: Oxford University Press; 2013 2013-10. 274 EuroQol Group. EuroQol--a new facility for the measurement of health-related 275 41. quality of life. Health Policy. 1990;16(3):199-208. 276 42. Sanderson TC, Hewlett SE, Flurey C, Dures E, Richards P, Kirwan JR. The 277 Impact Triad (Severity, Importance, Self-management) as a Method of Enhancing 278 Measurement of Personal Life Impact of Rheumatic Diseases. The Journal of 279 280 Rheumatology. 2011;38(2):191-4.

Refractory Inflammatory Arthritis revised definition and model

43. Codreanu C, Mogosan C, Ionescu R, Ancuta I, Opris D. Biologic therapy in
rheumatoid arthritis: results from the Romanian registry of rheumatic diseases one
year after initiation. Farmacia. 2014;62(6):1089-96.

44. Nordström DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K,
Forsberg S, et al. Classic disease modifying anti-rheumatic drugs (DMARDs) in
combination with infliximab. The Finnish experience. Rheumatology International.
2006;26(8):741-8.

45. Canhão H, Faustino A, Martins F, Fonseca JE. Reuma.pt - the rheumatic diseases portuguese register. Acta Reumatol Port. 2011;36(1):45-56.

46. Kuijper TM, Luime JJ, Alves C, Barendregt PJ, van Zeben J, Bindels PJ, et al.
Quality of life and health care use in patients with arthralgias without synovitis
compared with patients diagnosed with early rheumatoid arthritis: data from an early
arthritis cohort. Arthritis Care & Research. 2014;66(3):379-86.

47. Alves C, Luime JJ, van Zeben D, Huisman A-M, Weel AEAM, Barendregt PJ,
et al. Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid
arthritis and two diagnostic algorithms in an early arthritis clinic (REACH). Annals of
the rheumatic diseases. 2011;70(9):1645-7.

48. Oen K, Tucker L, Huber AM, Miettunen P, Scuccimarri R, Campillo S, et al.
Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a
Canadian multicenter, prospective inception cohort study. Arthritis Rheum.
2009;61(8):1077-86.

49. Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, McCROSKERY P,
et al. Rheumatoid arthritis disease-modifying antirheumatic drug intervention and
utilization study: safety and etanercept utilization analyses from the RADIUS 1 and
RADIUS 2 registries. The Journal of rheumatology. 2011;38(1):21-8.

Son Gerhold K, Richter A, Schneider M, Bergerhausen H-J, Demary W, Liebhaber
A, et al. Health-related quality of life in patients with long-standing rheumatoid
arthritis in the era of biologics: data from the German biologics register RABBIT.
Rheumatology. 2015;54(10):1858-66.

51. Sokka T, Kautiainen H, Toloza S, Mäkinen H, Verstappen SMM, Lund Hetland M, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Annals of the Rheumatic Diseases. 2007;66(11):1491-6.

52. Kvien TK, Uhlig T. The population based studies in rheumatoid arthritis. A method of longterm followup studies. The Journal of Rheumatology. 2004;69:35-40.

53. Minden K, Niewerth M, Listing J, Zink A. Health care provision in pediatric

rheumatology in Germany--national rheumatologic database. The Journal ofRheumatology. 2002;29(3):622-8.

54. Olsen I, Haavardsholm E, Moholt E, Kvien T, Lie E. NOR-DMARD data
management: implementation of data capture from electronic health records. Clin
Exp Rheumatol. 2014;32(5 Suppl 85):158-62.

55. Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(9):2809-18.

56. Symmons D, Silman A. The norfolk arthritis register (NOAR). Clinical and experimental rheumatology. 2003;21(5; SUPP 31):S94-S9.

327 57. Druce KL, Jones GT, Macfarlane GJ, Verstappen SMM, Basu N. The

Longitudinal Course of Fatigue in Rheumatoid Arthritis: Results from the Norfolk

Arthritis Register. The Journal of Rheumatology. 2015;42(11):2059-65.

Refractory Inflammatory Arthritis revised definition and model

58. Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid
arthritis. J Rheumatol Suppl. 2004;69:14-21.

332 59. British Society of Rheumatology. National Early Inflammatory Arthritis Audit
 333 (NEIAA) 1st Annual Report 2019 [Available from:

334 https://www.rheumatology.org.uk/Portals/0/Documents/Practice_Quality/Audit].

NEIA_Audit_report _October_2019 pdf. 2019.

Wolfe F, Michaud K. The National Data Bank for rheumatic diseases: a multiregistry rheumatic disease data bank. Rheumatology (Oxford). 2011;50(1):16-24.
Zink A, Listing J, Klindworth C, Zeidler H. The national database of the
German Collaborative Arthritis Centres: I. Structure, aims, and patients. Annals of
the Rheumatic Diseases. 2001;60(3):199-206.

- 62. van den Berg R, van der Heijde D, Landewé R, van Lambalgen K, Huizinga T.
 The METEOR initiative: the way forward for optimal, worldwide data integration to
 improve care for RA patients. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S-135-40.
- Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Longterm outcome of patients with JIA treated with etanercept, results of the biologic
 register JuMBO. Rheumatology (Oxford). 2012;51(8):1407-15.
- 347 64. Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al.
 348 Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in
 349 a large observational cohort study IORRA in Japan. Modern Rheumatology.
 350 2007;17(4):283-9.
- 65. Rayner L, Matcham F, Hutton J, Stringer C, Dobson J, Steer S, et al.
 Embedding integrated mental health assessment and management in general
 hospital settings: feasibility, acceptability and the prevalence of common mental
 disorder. General Hospital Psychiatry. 2014;36(3):318-24.
- Matcham F, Norton S, Steer S, Hotopf M. Usefulness of the SF-36 Health
 Survey in screening for depressive and anxiety disorders in rheumatoid arthritis.
 BMC Musculoskeletal Disorders. 2016;17(1):224.
- Sengler C, Klotsche J, Niewerth M, Liedmann I, Föll D, Heiligenhaus A, et al.
 The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an
 inactive disease state within the first year of specialised care: data from a German
 inception cohort. RMD Open. 2015;1(1):e000074.
- Massardo L, Pons-Estel BA, Wojdyla D, Cardiel MH, Galarza-Maldonado CM,
 Sacnun MP, et al. Early rheumatoid arthritis in Latin America: low socioeconomic
 status related to high disease activity at baseline. Arthritis care & research.
 2012;64(8):1135-43.
- 69. Lapadula G, Ferraccioli G, Ferri C, Punzi L, Trotta F. GISEA: an Italian biological agents registry in rheumatology. Reumatismo. 2011;63(3):155-64.
- Young A, Dixey J, Williams P, Prouse P, Cox N, Kiely P, et al. An evaluation
 of the strengths and weaknesses of a register of newly diagnosed rheumatoid
 arthritis, 1986-2010. Rheumatology (Oxford). 2011;50(1):176-83.
- 371 71. de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA,
- et al. The prevalence of clinical remission in RA patients treated with anti-TNF:
- results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
- 374 Rheumatology (Oxford). 2012;51(9):1610-7.
- 375 72. Ibfelt EH, Jensen DV, Hetland ML. The Danish nationwide clinical register for
 376 patients with rheumatoid arthritis: DANBIO. Clin Epidemiol. 2016;8:737-42.
- 377 73. Kremer JM. The Corrona US registry of rheumatic and autoimmune diseases.
 378 Clin Exp Rheumatol. 2016;34(5 Suppl 101):S96-s9.

Refractory Inflammatory Arthritis revised definition and model

74. Uitz E, Fransen J, Langenegger T, Stucki G. Clinical quality management in 379 rheumatoid arthritis: putting theory into practice. Rheumatology. 2000;39(5):542-9. 380 Eriksson JK, Askling J, Arkema EV. The Swedish Rheumatology Quality 75. 381 Register: optimisation of rheumatic disease assessments using register-enriched 382 data. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S-147-9. 383 Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius 76. 384 N, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann 385 Rheum Dis. 2006;65(6):707-12. 386 Önen F, Can G, Çapar S, Dalkılıç E, Pehlivan Y, Şenel S, et al. A real-life 387 77. analysis of patients with rheumatologic diseases on biological treatments: Data from 388 TURKBIO Registry. Eur J Rheumatol. 2022;9(2):82-7. 389 Marcos J, Waimann C, Dal Pra F, Hogrefe J, Retamozo S, Caeiro F, et al. 390 78. 391 General characteristics of an early arthritis cohort in Argentina. Rheumatology. 392 2010;50(1):110-6. Bykerk VP, JAMAL S, BOIRE G, HITCHON CA, HARAOUI B, POPE JE, et al. 79. 393 The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis 394 395 Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR Classification Criteria Present with Less Severe Disease Activity. The Journal of 396 Rheumatology. 2012;39(11):2071-80. 397 80. Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, et al. 398 The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: 399 design, rationale, and characteristics of patients enrolled in the first 12 months. 400 Pediatric Rheumatology. 2017;15(1):30. 401 Adib N, Hyrich K, Thornton J, Lunt M, Davidson J, Gardner-Medwin J, et al. 402 81. Association between duration of symptoms and severity of disease at first 403 presentation to paediatric rheumatology: results from the Childhood Arthritis 404 405 Prospective Study. Rheumatology. 2008;47(7):991-5. Hanns L, Cordingley L, Galloway J, Norton S, Carvalho LA, Christie D, et al. 406 82. Do depressive symptoms at disease onset associate with future disease activity for 407 adolescent patients with JIA? Results from the Childhood Arthritis Prospective Study 408 (CAPS). . Annals of Rheumatic Disease. 2016;75((Suppl2)):171. 409 410 83. McErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in 411 children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 412 2013;72(12):1983-8. 413 414 84. Hyrich K. STUDY PROTOCOL British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) v2.0 05122018. 2018. 415 Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, et al. Using 416 85. 417 genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis 418 Sequential Study. Rheumatology. 2010:50(1):40-6. 419 86. Thorne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ, et al. 420 Effectiveness and Safety of Infliximab in Rheumatoid Arthritis: Analysis From a 421 Canadian Multicenter Prospective Observational Registry. Arthritis Care & Research. 422 2014;66(8):1142-51. 423 87. Rotar Z, Hočevar A, Rebolj Kodre A, Praprotnik S, Tomšič M. Retention of the 424 second-line biologic disease-modifying antirheumatic drugs in patients with 425 426 rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the

427 BioRx.si registry. Clin Rheumatol. 2015;34(10):1787-93.

Refractory Inflammatory Arthritis revised definition and model

88. Rintelen B, Zwerina J, Herold M, Singer F, Hitzelhammer J, Halder W, et al. 428 Validity of data collected in BIOREG, the Austrian register for biological treatment in 429 rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. 430 BMC Musculoskeletal Disorders. 2016;17(1):358. 431 Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, et al. 432 89. Associations of disease activity and treatments with mortality in men with rheumatoid 433 arthritis: results from the VARA registry. Rheumatology. 2010;50(1):101-9. 434 Kovalchik SA, Charles-Schoeman C, Khanna D, Paulus HE. An association 435 90. study of disease activity score components and patient satisfaction with overall 436 health for early RA patients on non-biologic DMARD therapy. Rheumatol Int. 437 438 2012;32(9):2725-9. 91. Otten MH, Prince FHM, Anink J, ten Cate R, Hoppenreijs EPAH, Armbrust W, 439 440 et al. Effectiveness and safety of a second and third biological agent after failing 441 etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC 442 Register. Annals of the Rheumatic Diseases. 2013;72(5):721-7. Barnabe C, Crane L, White T, Hemmelgarn B, Kaplan GG, Martin L, et al. 443 92. 444 Patient-reported Outcomes, Resource Use, and Social Participation of Patients with Rheumatoid Arthritis Treated with Biologics in Alberta: Experience of Indigenous and 445 Non-indigenous Patients. The Journal of Rheumatology. 2018:45(6):760-5. 446 93. Nüßlein HG, Alten R, Galeazzi M, Lorenz H-M, Boumpas D, Nurmohamed 447 MT, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in 448 European and Canadian populations: a 6-month interim analysis of the 2-year, 449 450 observational, prospective ACTION study. BMC Musculoskeletal Disorders. 451 2014;15(1):14. 94. Horák P, Skácelová M, Hejduk K, Smržová A, Pavelka K. Abatacept and its 452 use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from 453 454 the ATTRA registry. Clinical Rheumatology. 2013;32(10):1451-8. Williams MP, Buchbinder R, March L, Lassere M. The Australian 455 95. Rheumatology Association Database (ARAD). Seminars in Arthritis and 456 457 Rheumatism. 2011;40(4):e2-e3. Singh G. Arthritis, Rheumatism and Aging Medical Information System Post-458 96. 459 Marketing Surveillance Program. The Journal of Rheumatology. 2001;28(5):1174-9. Karateev D, Satybaldyev A, Luchikhina E, Lukina G, Nasonov E, Artyomov A, 460 97. et al. AB1115 The Characteristics of Therapy of Patients with Rheumatoid Arthritis in 461 the Russian Federation According to the Russian Register. Annals of the Rheumatic 462 463 Diseases. 2015;74:1273.3-4. Hafström I, Ajeganova S, Andersson ML, Bala SV, Bergman S, Bremander A, 464 98. et al. A Swedish register-based, long-term inception cohort study of patients with 465 rheumatoid arthritis - results of clinical relevance. Open access rheumatology : 466 research and reviews. 2019;11:207-17. 467 468 99. Kearsley-Fleet L, Davies R, Baildam E, Beresford MW, Foster HE, Southwood TR, et al. Factors associated with choice of biologic among children with Juvenile 469 Idiopathic Arthritis: results from two UK paediatric biologic registers. Rheumatology. 470 2016;55(9):1556-65. 471 472 100. Hyrich K. CURRENT DOCUMENT LIST – Biologics for Children with Rheumatic Diseases (BCRD). 2022. 473 Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. 474 101. Safety and efficacy of combination of etanercept and methotrexate compared to 475 treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): 476 preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519-25. 477

Refractory Inflammatory Arthritis revised definition and model

102. Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G. Improvement 478 in health-related quality of life for children with juvenile idiopathic arthritis after start 479 of treatment with etanercept. Arthritis Care Res (Hoboken). 2014;66(2):253-62. 480 Sanchez-Piedra C, Hernández Miguel MV, Manero J, Roselló R, Sánchez-481 103. Costa JT, Rodríguez-Lozano C, et al. Objectives and methodology of BIOBADASER 482 phase III. Reumatología Clínica (English Edition). 2019;15(4):229-36. 483 Cuppen BVJ, Fu J, van Wietmarschen HA, Harms AC, Koval S, Marijnissen 484 104. ACA, et al. Exploring the Inflammatory Metabolomic Profile to Predict Response to 485 TNF-α Inhibitors in Rheumatoid Arthritis. PLOS ONE. 2016;11(9):e0163087. 486 Hays RD, Sherbourne CD, Mazel RM. The rand 36-item health survey 1.0. 487 105. 488 Health Economics. 1993;2(3):217-27. Felson DT, Feathers V, Naik C, Solomon DH, Weinblatt ME, Shadick N. 489 106. 490 Meaning of patient global assessment when joint counts are low in rheumatoid 491 arthritis. RMD Open. 2022;8(2):e002346. Osei-Bimpong A, Meek JH, Lewis SM. ESR or CRP? A comparison of their 492 107. clinical utility. Hematology. 2007;12(4):353-7. 493 494 108. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism 495 provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum 496 Dis. 2011;70(3):404-13. 497 van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, 498 109. 499 van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid 500 arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916-20. 501 Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A 502 110. simplified disease activity index for rheumatoid arthritis for use in clinical practice. 503 Rheumatology (Oxford). 2003;42(2):244-57. 504 Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, 505 111. et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a 506 patient-derived composite measure of impact of rheumatoid arthritis: a EULAR 507 initiative. Annals of the Rheumatic Diseases. 2011;70(6):935-42. 508 509 112. Hazes JM, Hayton R, Silman AJ. A reevaluation of the symptom of morning stiffness. J Rheumatol. 1993;20(7):1138-42. 510 Boonstra AM, Schiphorst Preuper HR, Balk GA, Stewart RE. Cut-off points for 511 113. mild, moderate, and severe pain on the visual analogue scale for pain in patients 512 513 with chronic musculoskeletal pain. Pain. 2014;155(12):2545-50. Nicklin J, Cramp F, Kirwan J, Greenwood R, Urban M, Hewlett S. Measuring 514 114. fatigue in rheumatoid arthritis: A cross-sectional study to evaluate the Bristol 515 516 Rheumatoid Arthritis Fatigue Multi-Dimensional questionnaire, visual analog scales, and numerical rating scales. Arthritis Care & Research. 2010;62(11):1559-68. 517 Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in 518 115. rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford). 519 2006;45(7):885-9. 520 116. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp 521 Rheumatol. 2005;23(5 Suppl 39):S14-8. 522 117. Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment 523 Scale: a simple measure of impairment in functioning. The British Journal of 524

525 Psychiatry. 2002;180(5):461-4.

Refractory Inflammatory Arthritis revised definition and model

- 526 118. Silke L, Kirresh O, Sturt J, Lempp H. Development of the Rheumatoid Arthritis
 527 Distress Scale (RADS) A New Tool to Identify Disease-Specific Distress in Patients
- 528 with Rheumatoid Arthritis. 2021;5(51):1-21.
- 529 119. Becede M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, et al.
- Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum.2019;49(2):211-7.
- 532 120. Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-
- inflammatory mechanisms in refractory rheumatoid arthritis. Nature ReviewsRheumatology. 2021;17:17-33.
- Melville AR, Kearsley-Fleet L, Buch MH, Hyrich KL. Understanding Refractory
 Rheumatoid Arthritis: Implications for a Therapeutic Approach. Drugs.
- 537 2020;80(9):849-57.
- 538 122. Lopez-Olivo MA, Zogala RJ, des Bordes J, Zamora NV, Christensen R, Rai D,
- 539 et al. Outcomes Reported in Prospective Long-Term Observational Studies and
- 540 Registries of Patients with Rheumatoid Arthritis Worldwide: An OMERACT
- 541 Systematic Review. Arthritis Care & Research. 2020;n/a(n/a).
- 542 123. Machado PM. Measurements, composite scores and the art of 'cutting-off'.
- Annals of the Rheumatic Diseases. 2016;75(5):787-90.
- 124. Messelink MA, Roodenrijs NMT, van Es B, Hulsbergen-Veelken CAR, Jong S,
- 545 Overmars LM, et al. Identification and prediction of difficult-to-treat rheumatoid
- arthritis patients in structured and unstructured routine care data: results from a
 hackathon. Arthritis Research & Therapy. 2021;23(1):184.
- 125. Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, Lafeber FPJG,
- Jacobs JWG, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and
- 550 burden of disease. Rheumatology. 2020;60(8):3778-88.

Fallent
Interviews
ICP Interviews / Focus Groups
Application of Biopsychosocial Theory
Systematic Review of Definitions

Dationt

Generation of initial components and domains for the definition by study team Generation of components for the model by study team

Delphi Nominal Group

Initial discussion sensechecking identified components due to multi-disciplinary rheumatology expertise on refractory disease

Voting on name preferences with further suggestions

Voting on inclusion and relatedness of proposed domains

Presentation of Model and Components to KCL Health Psychology Group

Model sense-checking and component feedback due to expertise on model and questionnaire development Further refinement to produce final components and domains for online Delphi definition voting by study team Online Voting

Voting on name preferences Voting on the inclusion of domains


Voting on the relatedness of components

Clarify wording and free text suggestions


Voting from wider international group to include broader experiences and knowledge

Analysis of ratings whether domains/components are included, modified or excluded with re-voting as appropriate Final refinement, analysis and generation of new definition and model by study team Theoretical validation through scoping review to test utility and identify further measures to operationalise definition by study team

Phase One







Components

